SCHEMBL25596207

SCHEMBL25596207

Cc1cc(CC(C)(C)N)ccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 13/20 0.59
ESR2 Q92731 8/20 0.59
PDE10A Q9Y233 1/20 0.50
TDP1 Q9NUW8 3/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
CYP1A2 P05177 2/20 0.49
POLB P06746 2/20 0.49
CYP3A4 P08684 2/20 0.49
MAPT P10636 2/20 0.49
HPGD P15428 2/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
MEN1 O00255 1/20 0.49
USP2 O75604 1/20 0.49
EGFR P00533 1/20 0.49
FYN P06241 1/20 0.49
GAA P10253 1/20 0.49
APEX1 P27695 1/20 0.49
ADRA1A P35348 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8601473 0.84 ESR1 (0.63) ESR1ESR2PDE10ATDP1KDM4E
SCHEMBL14478205 0.84 ALOX15 (0.66) ESR1TDP1KDM4EALDH1A1CYP1A2
SCHEMBL25596190 0.82 ESR1 (0.52) ESR1ESR2PDE10ATDP1KDM4E
SCHEMBL5511404 0.82 SLC6A2 (0.52) ESR1ESR2TDP1KDM4EALDH1A1
SCHEMBL6338791 0.81 TDP1 (0.77) ESR1ESR2PDE10ATDP1KDM4E
SCHEMBL2486290 0.81 TDP1 (0.77) ESR1ESR2PDE10ATDP1KDM4E
SCHEMBL6716878 0.81 TDP1 (0.58) ESR1ESR2PDE10ATDP1KDM4E
SCHEMBL10608436 0.81 TDP1 (0.77) ESR1ESR2PDE10ATDP1KDM4E
Hydrochloric Acid SCHEMBL1578093 0.80 TDP1 (0.74) ESR1ESR2PDE10ATDP1KDM4E
SCHEMBL8585296 0.79 SLC6A2 (0.46) ESR1ESR2KDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME SENDA BIOSCIENCES INC (US) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME COMT, SNCA, PARK7 ESR1 4421/4885ESR2 4494/4885PDE10A 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.